San Diego-based mostly Viking Therapeutics marked alone as a significant competitor while in the weight loss drug market place in February after revealing promising data from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection As well as in March t